Actinogen has fully randomized 247 patients to its Phase 2b/3 XanaMIA study in mild to moderate Alzheimer’s disease, and treatment initiation has been completed across all participants. The 36-week, double-blind trial compares once-daily Xanamem 10 mg to placebo with CDR-SB as the primary endpoint. An independent DMC will run a safety and futility analysis in late January 2026, and topline safety and efficacy readout for the whole cohort is slated for November 2026.
The update marks a faster-than-planned close to enrollment, with total accrual exceeding the original 220-participant target. The study is being conducted in the U.S. and Australia and requires blood-based pTau181 elevation to confirm diagnosis and enrich for progressive disease. All past and present participants are eligible for an open-label extension beginning in Q1 2026. Actinogen frames XanaMIA as the lead element of a pivotal program backed by prior signals: a 34-patient, biomarker-defined subgroup from the earlier XanADu trial that showed a favorable trend on CDR-SB at 12 weeks, cognition gains in older healthy volunteers across multiple doses, and a depressive symptom signal in a separate trial. A PET study has shown central target engagement of Xanamem, an 11β-HSD1 inhibitor designed to modulate brain cortisol levels.
Strategically, the company is positioning an oral small molecule against a market recalibrated by monoclonal antibodies that demand imaging-based eligibility, infusion infrastructure, and intensive safety monitoring. Blood pTau enrichment is a pragmatic screen that can compress timelines and reduce site burden relative to amyloid PET or CSF confirmation. The more provocative bet is the 36-week horizon with CDR-SB in a mild-to-moderate population; while faster decline at this stage can enable detectable separation, the window is short compared with the 12–18 months typically used for disease-slowing claims. The design leans heavily on a small, retrospective biomarker-defined signal and symptomatic readouts, which may translate into operational efficiency but raise questions about durability and the magnitude required to satisfy regulators after recent antibody approvals.
For sites and CROs, the operational profile is favorable: a once-daily oral therapy, biomarker screening anchored in widely deployable blood assays, and an open-label extension to sustain retention. Screen fail rates and cycle times should be lower than those in imaging-led AD programs, and MRI safety surveillance demands are minimal relative to those for anti-amyloid agents. Assay performance and standardization across regions will be a tactical issue for labs and vendors. Regulators will be looking for consistent effects across secondary endpoints and subgroups, and for clinically meaningful change on CDR-SB within a relatively short interval. Payers and HTA bodies, if engaged, will focus on effect size, functional impact, and safety versus recently introduced biologics.
Key watch items now are the late-January DMC outcome and any operational signals around adherence, dropout rates, and site-to-site variability that could dilute effect size. The company plans EMA engagement in Q2 2026 and will need clarity on CMC scale-up in parallel with data maturation. If the 36-week readout shows robust and reproducible separation, Actinogen could justify a streamlined path to a larger confirmatory study or negotiate alignment on registrational sufficiency; if effects are modest or inconsistent, a longer-duration Phase 3 with refined enrichment may be unavoidable. With timelines fixed and enrollment complete, the next inflection will be whether the futility check clears, setting up 2026 as a go/no-go year for an oral, biomarker-enriched AD strategy built for speed and site practicality.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
